Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,794 JPY | +1.10% |
|
+3.37% | +27.65% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Analyst opinion has improved significantly over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+27.65% | 4.04B | B+ | ||
+61.53% | 856B | C+ | ||
+38.95% | 631B | B | ||
-3.66% | 359B | C+ | ||
+15.06% | 325B | B- | ||
+9.18% | 297B | C+ | ||
+5.89% | 234B | A+ | ||
+16.53% | 226B | B- | ||
+15.67% | 177B | C+ | ||
+2.47% | 165B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 4536 Stock
- Ratings Santen Pharmaceutical Co., Ltd.